Brief: Odonate Therapeutics Announces Initiation Of CONTESSA, A Phase 3 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer
28/12/2017 14:00
Dec 28 (Reuters) - Odonate Therapeutics Inc ODT.O :
* ODONATE THERAPEUTICS ANNOUNCES INITIATION OF CONTESSA, A
PHASE 3
STUDY OF TESETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC BREAST CANCER
Source text for Eikon: ID:nBw4JH6c9a
Further company coverage: ODT.O
(((Bangalore.newsroom@thomsonreuters.com);))
Recent news on Odonate
See all newsBrief: Odonate Announces Expected Delisting Of Its Stock
Brief: Odonate Therapeutics Announces Planned Return Of Capital To Stockholders Through Share Repurchase Plan
Brief: Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58
Odonate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview